Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2936 (LINC02936)
- Target
- LINC02936
- Molecular classification
- Long non-coding RNA (lncRNA), Non-protein coding RNA
01
Overview
Long intergenic non-protein coding RNA 2936 (LINC02936) is a human long non-coding RNA (lncRNA) located on chromosome 2 and acts primarily within the cell nucleus. It promotes the progression of endometrial carcinoma by suppressing ferroptosis, mainly through interaction with the transcription factor SIX1 and regulation of the downstream effector CP (ceruloplasmin). Elevated LINC02936 expression is linked to increased tumor growth, invasion, and poor prognosis in EC. Its molecular action is relatively specific to cancer progression and ferroptosis suppression, with both mechanistic and clinical implications for endometrial carcinoma
- Other names
- AC017074.1LINC02936[3][7][9][10]
02
Mechanism of action
Long non-coding RNA acts by binding to the transcription factor SIX1, which in turn increases CP (ceruloplasmin) expression, reducing intracellular Fe²⁺ and ROS and suppressing ferroptosis in EC cells, thereby promoting tumor progression
03
Biological functions
Regulation of gene expression via interaction with transcription factors (e.g. SIX1)Suppression of ferroptosisPromotion of cell viability, proliferation, and invasion in endometrial carcinomaModulation of oxidative stress response via regulation of Ceruloplasmin (CP) expression
04
Disease associations
Cancer, specifically endometrial carcinoma (EC)Tumor progression, poor prognosis association
05
Safety considerations
Therapeutic targeting of LINC02936 may affect cancer cell viability, proliferation, invasion, and susceptibility to ferroptosis; possible risks relating to iron/copper metabolism dysregulation, but not yet fully established
06
Biomarkers
High expression of LINC02936 correlates with poor survival and advanced tumor stage in endometrial carcinomaLINC02936 expression associated with CP levels
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2936 (LINC02936).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2936 (LINC02936).